Serum IL‐22 binding protein as a marker for atopic dermatitis activity and response to dupilumab treatment

© 2022 John Wiley & Sons Ltd. We investigated here the interleukin-22 (IL-22)/IL-22 Binding Protein (IL-22BP) axis in Atopic Dermatitis (AD) and its modulation upon treatment with Dupilumab, and our findings support its relevance in the clinical management of severe AD.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical and experimental allergy 2022-06, Vol.52 (6), p.820-823
Hauptverfasser:	Varandas, Claudia, Santos, M. Conceição, Neto, Marta, Sousa, Ana E., Lopes, Anabela, Silva, Susana
Format:	Artikel
Sprache:	eng
Schlagworte:	Antibodies, Monoclonal - therapeutic use Antibodies, Monoclonal, Humanized - therapeutic use anti‐IL‐4R therapy Atopic dermatitis Biomarkers Dermatitis, Atopic - diagnosis Dermatitis, Atopic - drug therapy Eczema Humans IL‐22 IL‐22 binding protein Interleukin-22 Interleukins Monoclonal antibodies Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	© 2022 John Wiley & Sons Ltd. We investigated here the interleukin-22 (IL-22)/IL-22 Binding Protein (IL-22BP) axis in Atopic Dermatitis (AD) and its modulation upon treatment with Dupilumab, and our findings support its relevance in the clinical management of severe AD.
ISSN:	0954-7894 1365-2222
DOI:	10.1111/cea.14147